In our view, the DARA story is really starting to come together. We see Soltamox as a $25 million peak opportunity for DARA Bio. Soltamox is a U.S. FDA approved (in 2006) oral liquid formulation of ...
Sabby Management, Dara Biosciences: In a new 13G filing just reported to the SEC, Hal Mintz’s Sabby Management reported an 8.3% stake in DARA Biosciences Inc (NASDAQ:DARA) stock. Due to the nature of ...
Last November 2012, DARA Biosciences (DARA) announced it has submitted an application to the U.S. FDA requesting Orphan Drug designation on KRN5500 for the treatment of chronic chemotherapy-induced ...
Alpha Capital Anstalt: According to a recent SEC filing, Alpha Capital Anstalt now owns around 2.3 million shares of DARA Biosciences Inc (NASDAQ:DARA). Alpha reported a passive stake that amasses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback